Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on April 19, 2023. The filing addresses corporate governance changes, specifically the departure of a director and the nomination of a new director for the upcoming 2023 Annual Meeting of Stockholders scheduled for June 8, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Director Resignation: Mr. David Farner, a director nominee of UPMC, tendered his resignation from the Board of Directors. This action was triggered by UPMC's ownership of Class A common stock falling below the 40% threshold required under the Stockholders Agreement.
- Resignation Terms: The Board accepted Mr. Farner's resignation but agreed he will continue to serve through the 2023 Annual Meeting.
- New Nominee: The Board recommended Mr. Richard Jelinek for election at the 2023 Annual Meeting. Mr. Jelinek is a Managing Partner at Czech One Capital Partners and formerly served as Executive Vice President at Aetna, Inc. and CVS Health.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on business performance. The primary disclosure relates to the procedural requirement for director resignation due to share ownership changes. Investors are directed to the upcoming Proxy Statement for detailed information regarding director nominees and voting matters.
Key Facts for Investor Verification
- Verify the exact date and outcome of the 2023 Annual Meeting regarding the election of Mr. Richard Jelinek.
- Review the definitive Proxy Statement for details on the composition of the Board of Directors and any other governance changes.
- Confirm UPMC's current ownership percentage to understand the implications of the Stockholders Agreement on future board composition.
- Check for any subsequent filings regarding the transition of Mr. Farner's role post-Annual Meeting.